SCHEMBL2853871

SCHEMBL2853871

COC(=O)c1cccc(OCC#N)c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 2/20 0.45
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.41
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
SLC6A3 Q01959 2/20 0.40
JAK2 O60674 1/20 0.40
HPGD P15428 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 2/20 0.39
SLC6A4 P31645 1/20 0.39
TSHR P16473 1/20 0.39
BRPF1 P55201 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21434742 0.86 NPC1 (0.44) ALDH1A1KDM4EPDK1PDK2PDK3
SCHEMBL6948700 0.85 ALDH1A1 (0.52) ALDH1A1KDM4EHSD17B10POLBATM
SCHEMBL27248537 0.82 HCRTR1 (0.50) ALDH1A1KDM4EHSD17B10PDK1PDK2
SCHEMBL11128708 0.80 POLB (0.48) ALDH1A1KDM4EHSD17B10POLBATM
SCHEMBL21725198 0.79 ACACB (0.42) ALDH1A1KDM4EHSD17B10PDK1PDK2
SCHEMBL27249087 0.78 JAK2 (0.59) ALDH1A1KDM4EHSD17B10PDK1PDK2
SCHEMBL11128965 0.77 ABL1 (0.51) SLC6A3HPGDLMNASLC6A4MRGPRX4
SCHEMBL11129614 0.77 ABL1 (0.48) ALDH1A1SLC6A3LMNASLC6A4TSHR
SCHEMBL2192561 0.77 ALDH1A1 (0.47) ALDH1A1KDM4EHSD17B10POLBATM
SCHEMBL2861153 0.76 PDK1 (0.45) ALDH1A1KDM4EHSD17B10POLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 ALDH1A1 625/4885KDM4E 1242/4885HSD17B10 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.